Skip to main content

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance)

Publication ,  Conference
Nixon, AB; Halabi, S; Shterev, I; Starr, M; Brady, JC; Dutcher, JP; Hopkins, JO; Hurwitz, H; Small, EJ; Rini, BI; Febbo, PG; George, DJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2013

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2013

Volume

31

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nixon, A. B., Halabi, S., Shterev, I., Starr, M., Brady, J. C., Dutcher, J. P., … George, D. J. (2013). Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Nixon, Andrew B., Susan Halabi, Ivo Shterev, Mark Starr, John C. Brady, Janice P. Dutcher, Judith O. Hopkins, et al. “Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
Nixon AB, Halabi S, Shterev I, Starr M, Brady JC, Dutcher JP, Hopkins JO, Hurwitz H, Small EJ, Rini BI, Febbo PG, George DJ. Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2013

Volume

31

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences